Overall, this experiment demonstrated the versatility of Val-ILs in targeting and inducing cell death in specific leukemia subtypes by incorporating different antibodies, such as anti-CD7 for T-ALL and anti-CD33 for AML. Here, CD33 is linked to acute lymphoblastic leukemia.